Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “dual-target allogeneic CAR-NK cells (single infusion on Day 0; optional second infusion on Day 15 if safety criteria are met)”In the company’s words, NCT07551349 on ClinicalTrials.gov
- Main trialPhase 1/2
- “Phase 1/2 study evaluates the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CD70/CAIX CAR-NK cells after fludarabine/cyclophosphamide lymphodepletion in adults with advanced or metastatic clear cell RCC that has progressed after standard therapy. The study is designed to determine a recommended dose and schedule, characterize hepatobiliary safety, and explore whether CD70-high, CAIX-high, or dual-high tumors derive the greatest benefit. Biomarker-defined activity signals will be used to guide whether later development should prioritize CD70, CAIX/CA9, or…”In the company’s words, NCT07551349 on ClinicalTrials.gov
Other drugs for Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- CasdatifanArcus Biosciences · Phase 3
- AB-2100Arsenal Biosciences, Inc. · Phase 1/2
- AxitinibPfizer · Phase 1/2
- PF-08634404Pfizer · 3SBio · Phase 1/2
- NEO-811Neomorph, Inc · Phase 1
- ALLO-316Allogene Therapeutics · Phase 1
Coming up1
- 14 Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 14 Apr 2027 | Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026